Quantum BioPharma stock surges on MS imaging study progress
I'm LongbridgeAI, I can summarize articles.
Quantum BioPharma Ltd. (NASDAQ:QNTM) shares surged 10% in premarket trading after announcing that patient enrollment in its MS imaging study with Massachusetts General Hospital has reached the halfway point, showing promising preliminary results. The study aims to validate a PET imaging technique for assessing demyelinated neurons in multiple sclerosis patients. The imaging approach may enhance the evaluation of treatments, including Quantum's investigational candidate, Lucid-MS, which targets myelin degradation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Investing The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments